Medroxyprogesterone and tamoxifen augment anti-proliferative efficacy and reduce mitochondria-toxicity of epirubicin in FM3A tumor cells in vitro

Cell Biology International

Volumn 31, Issue 5, 2007, Pages 473-481

  Altinoz, Meric A ^a   Bilir, Ayhan ^b   Gedikoglu, Gunduz ^c   Ozcan, Emin ^d   Oktem, Gulperi ^b   Muslumanoglu, Mahmut ^a  

^a HALIC UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Bakirkoy State Hospital ^*

^d EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Epirubicin; Medroxyprogesterone; Tamoxifen

Indexed keywords

EPIRUBICIN; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CELL CYCLE S PHASE; CELL KINETICS; CHROMATIN; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; TOXICITY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DNA REPLICATION; DRUG SYNERGISM; EPIRUBICIN; FEMALE; HUMANS; KINETICS; MEDROXYPROGESTERONE; MITOCHONDRIA; TAMOXIFEN;

EID: 34247249742     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2006.11.013     Document Type: Article

References (66)

1. Altinoz M.A., Bilir A., Ozar E., Onar F.D., and Sav A. Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. Int J Dev Neurosci 19 (2001) 541-547
2. Altinoz M.A., Ozar E., Taskin M., Bozcali E., Bilir A., Altug T., et al. Vascularization pattern of C6 glioma is modified with medroxyprogesterone acetate and ibuprofen in Wistar rat brain. Pathol Oncol Res 7 (2001) 185-189
3. Baguley B.C., Turner P.M., and Ferguson L.R. Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisae. Eur J Cancer 26 (1990) 55-60
4. Bilir A., Altinoz M.A., Erkan M., Ozmen V., and Aydiner A. Autophagy and nuclear changes in FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro. Pathobiology 69 (2001) 120-126
5. Blagoskonny M.V., and El Deiry W.S. Acute overexpression of wt p53 facilitates anticancer drug- induced death of cancer and normal cells. Int J Cancer 75 (1998) 933-940
6. Bottini A., Berruti A., Brizzi M.P., Bersiga A., Generali D., Allevi G., et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 12 (2005) 383-392
7. Bradbury B.D., Lash T.L., Kaye J.A., and Jick S.S. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 103 (2005) 1114-1121
8. Cohen V.M., Moosavi R., and Hungerford J.L. Tamoxifen-induced regression of a choroidal metastasis in a man. Arch Ophthalmol 123 8 (2005 Aug) 1153-1154
9. Davidson N.E., O'Neill A.M., Vukov A.M., Osborne C.K., Martino S., White D.R., et al. Chemo- endocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23 (2005) 5973-5982
10. Daxnerova Z., and Mitro A. The nucleolar channel system of nerve cell. Short communication. J Hirnforsch 25 (1984) 309-311
11. Etienne M.C., Milano G., Fischel J.L., Frenay M., Francois E., Formento J.L., et al. Tamoxifen metabolism: pharmacokinetic and in vitro study. Br J Cancer 60 (1989) 30-35
12. Fattman C.L., An B., Sussman L., and Dou Q.P. p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen induced apoptosis in human breast carcinoma cells. Cancer Lett 30 (1998) 103-113
13. Florio S., Crispino L., Ciarcia R., Vacca G., Pagnini U., de Matteis A., et al. MPA increases idarubicin-induced apoptosis in chronic lymphatic leukaemia cells via caspase-3. J Cell Biochem 89 (2003) 747-754
14. Forcet C., Ye X., Granger L., Corset V., Shin H., Bredesen D.E., et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci USA 98 (2001) 3416-3421
15. Formby B., and Wiley T.S. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on bcl-2 and p53. Ann Clin Lab 28 (1998) 360-369
16. Fyles A.W., McCready D.R., Manchul L.A., Trudeau M.E., Merante P., Pintilie M., et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351 (2004) 963-970
17. Garvin S., and Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63 (2003) 8742-8748
18. Gong Y., Wang Y., Chen F., Han J., Miao J., Shao N., et al. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leuk Res 24 (2000) 769-774
19. Hackenbrock C.R. Ultrastructural basis for metabolically linked mechanical activity in mitochondria. I. Reversible ultrastructural changes with changes in metabolic steady state in isolated liver mitochondria. J Cell Biol 30 (1966) 269-297
20. Hackenbrock C.R. Ultrastructural basis for metabolically linked mechanical activity in mitochondria. II. Electron transport-linked ultrastructural transformations in mitochondria. Cell Biol 37 (1968) 345-369
21. Horbelt D.V., Delmore J.E., Parmley T.H., Roberts D.K., and Walker N. The nuclear channel system in endometrial adenocarcinoma exposed to medroxyprogesterone acetate. Hum Pathol 27 (1996) 9-14
22. Hupperets P.S., Wils J.A., Volovics L., Schouten L.J., Fickers M.M., Bron H.N., et al. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up. Breast 10 (2001) 35-37
23. Iino Y., Ishikawa H., Izuo M., and Takikawa H. Sequential hormone therapy with medroxyprogesterone acetate for 7,12-dimethylbenz (alpha) anthracene-induced rat mammary tumors. Jpn J Clin Oncol 19 (1989) 45-50
24. Ishikawa T., Takashima T., Takagaki K., Ogawa Y., Onoda N., Nakata B., et al. A case of anthracycline and taxane-resistant breast cancer with life-threatening multiple liver metastases responding to oral combination chemotherapy by UFT, cyclophosphamide and medroxyprogesterone acetate. Gan To Kagaku Ryoho 32 (2005) 687-690
25. Jezierska A., Matysiak W., and Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 12 (2006) BR263-BR273
26. Jia L., Dourmashkin R.R., Newland A.C., and Kelsey S.M. Mitochondrial ultra-condensation, but not swelling, is involved in TNF alpha-induced apoptosis in human T-lymphoblastic leukaemic cells. Leuk Res 21 (1997) 973-983
27. Jouvet P., Rustin P., Taylor D.L., Pocock J.M., Felderhoff-Mueser U., Mazarakis N.D., et al. Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell 11 (2000) 1919-1932
28. Jung D.W., and Brierley G.P. Progesterone stimulates energy-dependent contraction of swollen heart mitochondria. Experientia 37 (1981) 237-238
29. Kallio A., Zheng A., Dahllund J., Heiskanen K.M., and Harkonen P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10 (2005) 1395-1410
30. Kerr J.F. Shrinkage necrosis: a distinct mode of cellular death. J Pathol 105 (1971) 13-20
31. Kohorn E.I., Rice S.I., Hemperly S., and Gordon M. The relation of the structure of progestational steroids to nucleolar differentiation in human endometrium. J Clin Endocrinol Metab 34 (1972) 257-264
32. Laiho K.U., and Trump B.F. Studies on the pathogenesis of cell injury: effects of inhibitors of metabolism and membrane function on the mitochondria of Ehrlich ascites tumor cells. Lab Invest 32 (1975) 163-182
33. Lavie Y., Zhang Z.C., Cao H.T., Han T.Y., Jones R.C., Liu Y.Y., et al. Tamoxifen induces selective membrane association of Protein Kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 77 (1998) 928-932
34. Leonessa F., Jacobson M., Boyle B., Lippman J., McGarvey M., and Clarke R. Effect of tamoxifen on the multi-drug resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r)170,000 glycoprotein (gp170) binding studies. Cancer Res 54 (1994) 441-447
35. Liu Z., Shi H.Y., Nawaz Z., and Zhang M. Tamoxifen induces the expression of maspin through estrogen receptor-alpha. Cancer Lett 209 (2004) 55-65
36. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., and Cabot M.C. Multidrug resistance modulators and doxorubicin synergies to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86 (1999) 300-311
37. Manders P., Beex L.V., Tjan-Heijnen V.C., Span P.N., and Sweep C.G. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98 (2003) 2125-2132
38. Nakajima Y., Hirayama K., Saitoh K., Terashima H., Shimada T., Nishiyama S., et al. An elderly woman with breast cancer and multiple liver metastasis that responded well to combination therapy of fadrozole and tamoxifen. Gan To Kagaku Ryoho 28 (2001) 2065-2068
39. Nishimura H., Takasuna K., Kondo R., Hayashi K., Munakata Y., and Kasuga Y. A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy. Gan To Kagaku Rhoyo 27 (2000) 753-757
40. Noguchi S., Koyama H., Uchino J., Abe R., Miura S., Sugimachi K., et al. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23 (2005) 2172-2184
41. Ormrod D., Holm K., Goa K., and Spencer C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 15 (1999) 389-416
42. Osborn C.K. Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat 1 (1981) 121-123
43. Osborn C.K., Boldt D.H., and Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in human culture. Cancer Res 44 (1984) 1433-1439
44. Ozmen V., Cabioglu N., Dolay K., Bilir A., Kecer M., Aydiner A., et al. Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome. Breast Cancer Res Treat 68 (2001) 147-157
45. Palmieri D., Halverson D.O., Ouatas T., Horak C.E., Salerno M., Johnson J., et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 97 (2005) 632-642
46. Papadimitriou J.C., Drachenberg C.B., Shin M.L., and Trump B.F. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch 424 (1994) 677-685
47. Pietras R.J. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 11 (2006) 704-717
48. Piwocka K., Zablocki K., Wieckowski M.R., Skierski J., Feiga I., Szopa J., et al. A novel apoptosis-like pathway, independent of mitochondria and caspases, induced by Curcumin in human lymphoblastoid T (Jurkat) cells. Exp Cell Res 249 (1999) 299-307
49. Pollack I.F., Randall M.S., and Kristofik M.P. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma cells in vitro. Cancer Res 50 (1990) 7134-7138
50. Robinson S.P., Langan-Fahey S.M., and Jordan V.C. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Clin Oncol 25 (1989) 1769-1776
51. Sargent J.M., Williamson C.J., Yardley C., Taylor C.G., and Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer 84 (2001) 959-964
52. Saxena S., Jain A.K., Pandey K.K., and Dewan A.K. Role of steroid hormone and growth factor receptors and proto-oncogenes in the behavior of human mammary epithelial cancer cells in vitro. Pathobiology 65 (1997) 75-82
53. Schmidberger H., Hermann R.M., Hess C.F., and Emons G. Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer 10 (2003) 375-388
54. Seifert C.F., Nesser M.E., and Thompson D.F. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28 (1994) 1063-1072
55. Sperandio S., de Belle I., and Bredesen D.E. An alternative, non-apoptotic form of programmed cell death. Proc Natl Acad Sci USA 97 (2000) 14376-14381
56. Spitaler M., Wiesenhofer B., and Biedermann V. The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res 19 (1999) 3969-3976
57. Tamura H., Kojima M., Kobayashi H., Ando J., Oka S., Fujisaki M., et al. Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy. Gan To Kagaku Ryoho 27 (2000) 993-1002
58. Terazaki Y., Nagamatsu H., Ono H., Iwakuma N., and Shirouzu K. A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia. Gan To Kagaku Rhoyo 32 (2005) 675-677
59. Thurlimann B., Robertson J.F., Nabholtz J.M., Buzdar A., Bonneterre J., and Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39 (2003) 2310-2317
60. Vaidyanathan S., and Boroujerdi M. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats. Cancer Chemother Pharmacol 46 (2000) 185-192
61. Yamaguchi S., Fukuda M., Ota T., Nakayama Y., Ogata H., Shimizu K., et al. A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer. Gan To Kagaku Rhoyo 26 (1999) 1145-1152
62. Yasuzumi G., Yabumoto N., Saito K., and Tsubo I. In vivo production of nucleolar channel system in human endocervical secretory cells. J Submicrosc Cytol 13 (1981) 639-647
63. Yuyama Y., Yagihashi A., Hirata K., Suzuki Y., Ohmura T., Okazaki M., et al. The effects of epirubicin hydrochloride (EPI) plus pretreatment of medroxyprogesterone acetate (MPA) on FM3A breast cancer cells transplanted in female C3H/He mice. In vivo 17 (2003) 251-254
64. Zaucha R., Sosinska-Mielcarek K., and Jassem J. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. Breast 13 (2004) 321-324
65. Zhao Y., Wang L.M., Chaiswing L., Yen H.C., Oberley T.D., Lien Y.C., et al. Tamoxifen protects against acute tumor necrosis factor alpha-induced cardiac injury via improving mitochondrial functions. Free Radic Biol Med 40 (2006) 1234-1241
66. Zibera C., Gibelli N., Maestri L., and Della Cuna G.R. Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line. Anticancer Res 15 (1995) 745-750